B of A Securities Maintains Buy on BridgeBio Pharma, Lowers Price Target to $42
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Geoff Meacham maintains a Buy rating on BridgeBio Pharma (NASDAQ:BBIO) but lowers the price target from $50 to $42.
June 25, 2024 | 4:48 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
B of A Securities analyst Geoff Meacham maintains a Buy rating on BridgeBio Pharma but lowers the price target from $50 to $42.
The Buy rating suggests continued confidence in BridgeBio Pharma's long-term prospects, but the lowered price target indicates some caution regarding short-term performance. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100